Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

On May 15, 2024 IMUNON, a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, reported that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, to be held in Chicago from May 31st to June 4th (Press release, IMUNON, MAY 15, 2024, View Source [SID1234643322]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy when administered in combination with bevacizumab and neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer," will be presented on June 3rd at the Gynecologic Cancer session between 9:00 a.m. and 12:00 p.m. CT by lead investigator Amir A Jazaeri, M.D., Professor of Gynecological Oncology & Reproductive Medicine at The University of Texas MD Anderson Cancer Center. The study is actively recruiting patients in the U.S.

Abstract #: TPS5633
Poster Board #: 498a
Session Title: Gynecologic Cancer
Location: Hall A

"This study, substantially funded by Break Through Cancer, and with MD Anderson as the leading clinical site, is a pivotal part of IMUNON’s IL-12 gene therapy development for women with ovarian cancer. The combination with bevacizumab makes a lot of sense as we have observed synergies in pre-clinical experiments. We hope to complete enrollment of this study quickly to answer this important clinical question," said Dr. Sebastien Hazard, IMUNON’ chief medical officer.